{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:54:48Z","timestamp":1794567288921,"version":"4.9.1"},"publisher-location":"New York, NY","reference-count":118,"publisher":"Springer New York","isbn-type":[{"value":"9781493978243","type":"print"},{"value":"9781493978250","type":"electronic"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1007\/978-1-4939-7825-0_10","type":"book-chapter","created":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T08:44:16Z","timestamp":1527756256000},"page":"179-207","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Murine Models of Huntington\u2019s Disease for Evaluating Therapeutics"],"prefix":"10.1007","author":[{"given":"Natalia","family":"Kosior","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blair R.","family":"Leavitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,1]]},"reference":[{"key":"10_CR1","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/mds.25075","volume":"27","author":"T Pringsheim","year":"2012","unstructured":"Pringsheim T, Wiltshire K, Day L et al (2012) The incidence and prevalence of Huntington\u2019s disease: a systematic review and meta-analysis. Mov Disord 27:1083\u20131091","journal-title":"Mov Disord"},{"issue":"2","key":"10_CR2","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000443738","volume":"46","author":"MD Rawlins","year":"2016","unstructured":"Rawlins MD, Wexler NS, Wexler AR et al (2016) The prevalence of Huntington\u2019s disease. Neuroepidemiology 46(2):144\u2013153","journal-title":"Neuroepidemiology"},{"issue":"1","key":"10_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/mds.25717","volume":"29","author":"ER Fisher","year":"2014","unstructured":"Fisher ER, Hayden MR (2014) Multisource ascertainment of Huntington\u2019s disease in Canada: prevalence and population at risk. Mov Disord 29(1):105\u2013114","journal-title":"Mov Disord"},{"issue":"5940","key":"10_CR4","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/306234a0","volume":"306","author":"JF Gusella","year":"1983","unstructured":"Gusella JF, Wexler NS, Conneally PM et al (1983) A polymorphic DNA marker genetically linked to Huntington\u2019s disease. Nature 306(5940):234\u2013238","journal-title":"Nature"},{"issue":"6","key":"10_CR5","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"Anon","year":"1993","unstructured":"Anon et al (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. The Huntington\u2019s Disease Collaborative Research Group. Cell 72(6):971\u2013983","journal-title":"Cell"},{"issue":"4","key":"10_CR6","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00439-011-1119-1","volume":"131","author":"MA Gama Sosa","year":"2012","unstructured":"Gama Sosa MA, De Gasperi R, Elder GA (2012) Modeling human neurodegenerative diseases in transgenic systems. Hum Genet 131(4):535\u2013563","journal-title":"Hum Genet"},{"key":"10_CR7","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/B978-0-12-373861-5.00018-7","volume-title":"Animal and Translational Models for CNS Drug Discovery","author":"Laura A. Wagner","year":"2008","unstructured":"Wagner LA, Menalled L, Goumeniouk\u00a0A et al (2008) Chapter 6: Huntington\u2019s disease. In MacArthur, RA and Borsini F (eds.): Animal and Translational Models for CNS Drug Discovery: Neurological Disorders pp 207\u2013266"},{"issue":"12","key":"10_CR8","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1177\/014107680509801216","volume":"98","author":"Ben Harper","year":"2005","unstructured":"Harper B (2005) Huntington disease (online). Available from: https:\/\/doi.org\/10.1258\/jrsm.98.12.550","journal-title":"Journal of the Royal Society of Medicine"},{"issue":"2","key":"10_CR9","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1212\/WNL.36.2.244","volume":"36","author":"AB Young","year":"1986","unstructured":"Young AB, Shoulson I, Penney JB et al (1986) Huntington\u2019s disease in Venezuela: neurologic features and functional decline. Neurology 36(2):244\u2013249","journal-title":"Neurology"},{"issue":"3","key":"10_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/mrdd.1022","volume":"7","author":"MA Nance","year":"2001","unstructured":"Nance MA, Myers RH (2001) Juvenile onset Huntington\u2019s disease: clinical and research perspectives. Ment Retard Dev Disabil Res Rev 7(3):153\u2013157","journal-title":"Ment Retard Dev Disabil Res Rev"},{"issue":"6","key":"10_CR11","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/0028-3932(85)90080-6","volume":"23","author":"N Butters","year":"1985","unstructured":"Butters N, Wolfe J, Martone M et al (1985) Memory disorders associated with Huntington\u2019s disease: verbal recall, verbal recognition and procedural memory. Neuropsychologia 23(6):729\u2013743","journal-title":"Neuropsychologia"},{"issue":"4","key":"10_CR12","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1076\/jcen.20.4.565.1468","volume":"20","author":"KK Zakzanis","year":"1998","unstructured":"Zakzanis KK (1998) The subcortical dementia of Huntington\u2019s disease. J Clin Exp Neuropsychol 20(4):565\u2013578","journal-title":"J Clin Exp Neuropsychol"},{"issue":"5","key":"10_CR13","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s11920-996-0030-2","volume":"3","author":"KE Anderson","year":"2001","unstructured":"Anderson KE, Marder KS (2001) An overview of psychiatric symptoms in Huntington\u2019s disease. Curr Psychiatry Rep 3(5):379\u2013388","journal-title":"Curr Psychiatry Rep"},{"issue":"2","key":"10_CR14","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1136\/jmg.33.2.128","volume":"33","author":"S Lovestone","year":"1996","unstructured":"Lovestone S, Hodgson S, Sham P et al (1996) Familial psychiatric presentation of Huntington\u2019s disease. J Med Genet 33(2):128\u2013131","journal-title":"J Med Genet"},{"issue":"8","key":"10_CR15","doi-asserted-by":"crossref","first-page":"407","DOI":"10.5694\/j.1326-5377.1981.tb135681.x","volume":"1","author":"PR Sanberg","year":"1981","unstructured":"Sanberg PR, Fibiger HC, Mark RF et al (1981) Body weight and dietary factors in Huntington\u2019s disease patients compared with matched controls. Med J Aust 1(8):407\u2013409","journal-title":"Med J Aust"},{"issue":"1","key":"10_CR16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1523\/JNEUROSCI.3842-04.2005","volume":"25","author":"AJ Morton","year":"2005","unstructured":"Morton AJ, Wood NI, Hastings MH et al (2005) Disintegration of the sleep-wake cycle and circadian timing in Huntington\u2019s disease. J Neurosci 25(1):157\u2013163","journal-title":"J Neurosci"},{"issue":"3","key":"10_CR17","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.nbd.2007.01.006","volume":"26","author":"JM Raamsdonk Van","year":"2007","unstructured":"Van Raamsdonk JM, Murphy Z, Selva DM et al (2007) Testicular degeneration in Huntington disease. Neurobiol Dis 26(3):512\u2013520","journal-title":"Neurobiol Dis"},{"issue":"5","key":"10_CR18","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/0896-6273(95)90345-3","volume":"14","author":"AH Sharp","year":"1995","unstructured":"Sharp AH, Loev SJ, Schilling G et al (1995) Widespread expression of Huntington\u2019s disease gene (IT15) protein product. Neuron 14(5):1065\u20131074","journal-title":"Neuron"},{"issue":"4","key":"10_CR19","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/ng0893-398","volume":"4","author":"SE Andrew","year":"1993","unstructured":"Andrew SE, Goldberg YP, Kremer B et al (1993) The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington\u2019s disease. Nat Genet 4(4):398\u2013403","journal-title":"Nat Genet"},{"issue":"5049","key":"10_CR20","first-page":"1235","volume":"225","author":"M Mahadevan","year":"1992","unstructured":"Mahadevan M, Tsilfidis C, Sabourin L et al (1992) Mytonic dystrophy mutation: an unstable CTG repeat in the 3\u2032 untranslated region of the gene. Science 225(5049):1235\u20131255","journal-title":"Science"},{"issue":"4","key":"10_CR21","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1399-0004.2006.00668.x","volume":"70","author":"A Semaka","year":"2006","unstructured":"Semaka A, Creighton S, Warby S, Hayden MR et al (2006) Predictive testing for Huntingons disease: interpretation and significance of intermediate alleles. Clin Genet 70(4):283\u2013294","journal-title":"Clin Genet"},{"issue":"10","key":"10_CR22","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1093\/hmg\/2.10.1535","volume":"2","author":"H Telenius","year":"1993","unstructured":"Telenius H, Kremer HP, Theilmann J et\u00a0al (1993) Molecular analysis of juvenile Huntington\u2019s disease: the major influence on (CAG)n repeat length is the sex of the affected parent. Hum Mol Genet 2(10):1535\u20131540","journal-title":"Hum Mol Genet"},{"issue":"6","key":"10_CR23","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/nn.4014","volume":"18","author":"K Becanovic","year":"2015","unstructured":"Becanovic K, Norremolle A, Neal SJ et al (2015) A SNP in the HTT promoter alters NF-kB binding and is a bidirectional genetic modifier of Huntington\u2019s disease. Nat Neurosci 18(6):807\u2013816","journal-title":"Nat Neurosci"},{"issue":"3","key":"10_CR24","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.cell.2015.07.003","volume":"162","author":"Genetic Modifiers of Huntington\u2019s Disease (GeM-HD) Consortium","year":"2015","unstructured":"Genetic Modifiers of Huntington\u2019s Disease (GeM-HD) Consortium (2015) Identification of genetic factors that modify clinical onset of Huntington\u2019s disease. Cell 162(3):516\u2013526","journal-title":"Cell"},{"issue":"5","key":"10_CR25","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/00005072-199805000-00001","volume":"57","author":"JP Vonsattel","year":"1998","unstructured":"Vonsattel JP, DiFiglia M (1998) Huntington\u2019s disease. J Neuropathol Exp Neurol 57(5):369\u2013384","journal-title":"J Neuropathol Exp Neurol"},{"issue":"6","key":"10_CR26","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","volume":"44","author":"JP Vonsattel","year":"1985","unstructured":"Vonsattel JP, Myers RH, Stevens TJ et al (1985) Neuropathological classification of Huntington\u2019s disease. J Neuropathol Exp Neurol 44(6):559\u2013577","journal-title":"J Neuropathol Exp Neurol"},{"issue":"3","key":"10_CR27","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S0092-8674(00)80513-9","volume":"90","author":"SW Davies","year":"1997","unstructured":"Davies SW, Turmaine M, Cozens BA et al (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90(3):537\u2013548","journal-title":"Cell"},{"issue":"5334","key":"10_CR28","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","volume":"277","author":"M DiFiglia","year":"1997","unstructured":"DiFiglia M, Sapp E, Chase KO et al (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neuritis in brain. Science 277(5334):1990\u20131993","journal-title":"Science"},{"issue":"5574","key":"10_CR29","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/263244a0","volume":"263","author":"JT Coyle","year":"1976","unstructured":"Coyle JT, Schwarcz R (1976) Lesion of striatal neurones with kainic acid provides a model for Huntington\u2019s chorea. Nature 263(5574):244\u2013246","journal-title":"Nature"},{"issue":"6","key":"10_CR30","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1523\/JNEUROSCI.11-06-01649.1991","volume":"11","author":"MF Beal","year":"1991","unstructured":"Beal MF, Ferrante RJ, Swartz KJ, Kowall NW (1991) Chronic quinolinic acid lesions in rats closely resemble Huntingtons-disease. J Neurosci 11(6):1649\u20131659","journal-title":"J Neurosci"},{"issue":"4","key":"10_CR31","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1017\/S0317167100032212","volume":"18","author":"AC Ludolph","year":"1991","unstructured":"Ludolph AC, He F, Spencer PS et al (1991) 3-Nitropropionic acid\u00a0\u2013 exogenous animal neurotoxin and possible human striatal toxin. Can J Neurol Sci 18(4):492\u2013498","journal-title":"Can J Neurol Sci"},{"issue":"3","key":"10_CR32","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","volume":"87","author":"L Mangiarini","year":"1996","unstructured":"Mangiarini L, Sathasivam K, Seller M et al (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87(3):493\u2013506","journal-title":"Cell"},{"issue":"8","key":"10_CR33","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1523\/JNEUROSCI.19-08-03248.1999","volume":"19","author":"RJ Carter","year":"1999","unstructured":"Carter RJ, Lione LA, Humby T et al (1999) Characterization of progressive motor deficits in mice transgenic for the human Huntington\u2019s disease mutation. J Neurosci 19(8):3248\u20133257","journal-title":"J Neurosci"},{"issue":"3","key":"10_CR34","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1602\/neurorx.2.3.447","volume":"2","author":"JY Li","year":"2005","unstructured":"Li JY, Popovic N, Brundin P et al (2005) The use of the R6 transgenic mouse models of Huntington\u2019s disease in attempts to develop novel therapeutic strategies. NeuroRx 2(3):447\u2013464","journal-title":"NeuroRx"},{"issue":"3","key":"10_CR35","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/hmg\/8.3.397","volume":"8","author":"G Schilling","year":"1999","unstructured":"Schilling G, Becher MW, Sharp AH et al (1999) Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet 8(3):397\u2013407","journal-title":"Hum Mol Genet"},{"issue":"9","key":"10_CR36","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1093\/hmg\/9.9.1259","volume":"9","author":"R Luthi-Carter","year":"2000","unstructured":"Luthi-Carter R, Strand A, Peters NL et al (2000) Decreased expression of striatal signaling genes in a mouse model of Huntington\u2019s disease. Hum Mol Genet 9(9):1259\u20131271","journal-title":"Hum Mol Genet"},{"issue":"3","key":"10_CR37","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1006\/nbdi.2001.0406","volume":"8","author":"OA Andreassen","year":"2001","unstructured":"Andreassen OA, Dedeoglu A, Ferrante RJ et al (2001) Creatine increase survival and delays motor symptoms in transgenic animal model of Huntington\u2019s disease. Neurobiol Dis 8(3):479\u2013491","journal-title":"Neurobiol Dis"},{"issue":"1","key":"10_CR38","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/ana.1085","volume":"50","author":"OA Andreassen","year":"2001","unstructured":"Andreassen OA, Ferrante RJ, Huang HM et al (2001) Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington\u2019s disease. Ann Neurol 50(1):112\u2013117","journal-title":"Ann Neurol"},{"issue":"15","key":"10_CR39","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1097\/00001756-200110290-00044","volume":"12","author":"OA Andreassen","year":"2001","unstructured":"Andreassen OA, Ferrante RJ, Dedeoglu A, Beal MF et al (2001) Lipoic acid improves survival in transgenic mouse models of Huntington\u2019s disease. Neuroreport 12(15):3371\u20133373","journal-title":"Neuroreport"},{"issue":"3","key":"10_CR40","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0304-3940(01)02326-6","volume":"315","author":"G Schilling","year":"2001","unstructured":"Schilling G, Coonfield ML, Ross CA, Borchelt DR et al (2001) Coenzyme Q1 and remacemide hydrochloride ameloriate motor deficits in Huntington\u2019s disease transgenic mouse model. Neurosci Lett 315(3):149\u2013153","journal-title":"Neurosci Lett"},{"issue":"32","key":"10_CR41","doi-asserted-by":"publisher","first-page":"11402","DOI":"10.1073\/pnas.0503634102","volume":"102","author":"EJ Slow","year":"2005","unstructured":"Slow EJ, Graham RK, Osmand AP et al (2005) Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc Natl Acad Sci U S A 102(32):11402\u201311407","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1386","key":"10_CR42","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1098\/rstb.1999.0456","volume":"354","author":"PH Reddy","year":"1999","unstructured":"Reddy PH, Charles V, Williams M et al (1999) Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington\u2019s disease. Philos Trans R Soc Lond Ser B Biol Sci 354(1386):1035\u20131045","journal-title":"Philos Trans R Soc Lond Ser B Biol Sci"},{"issue":"2","key":"10_CR43","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.nbd.2005.07.014","volume":"21","author":"Y Tanaka","year":"2006","unstructured":"Tanaka Y, Igarashi S, Nakamura M et al (2006) Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin. Neurobiol Dis 21(2):381\u2013391","journal-title":"Neurobiol Dis"},{"issue":"1","key":"10_CR44","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0896-6273(00)80764-3","volume":"23","author":"JG Hodgson","year":"1999","unstructured":"Hodgson JG, Agopyan N, Gutekunst CA et al (1999) A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23(1):181\u2013192","journal-title":"Neuron"},{"issue":"13","key":"10_CR45","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1093\/hmg\/ddg169","volume":"12","author":"EJ Slow","year":"2003","unstructured":"Slow EJ, van Raamsdonk J, Rogers D et al (2003) Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 12(13):1555\u20131567","journal-title":"Hum Mol Genet"},{"issue":"16","key":"10_CR46","doi-asserted-by":"publisher","first-page":"4169","DOI":"10.1523\/JNEUROSCI.0590-05.2005","volume":"25","author":"JM Raamsdonk Van","year":"2005","unstructured":"Van Raamsdonk JM, Pearson J, Slow EJ et al (2005) Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington\u2019s disease. J Neurosci 25(16):4169\u20134180. https:\/\/doi.org\/10.1523\/JNEUROSCI.0590-05.2005","journal-title":"J Neurosci"},{"issue":"24","key":"10_CR47","doi-asserted-by":"publisher","first-page":"6182","DOI":"10.1523\/JNEUROSCI.0857-08.2008","volume":"28","author":"M Gray","year":"2008","unstructured":"Gray M, Shirasaki DI, Cepeda C et al (2008) Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci 28(24):6182\u20136195. https:\/\/doi.org\/10.1523\/JNEUROSCI.0857-08.2008","journal-title":"J Neurosci"},{"issue":"2","key":"10_CR48","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/BF02290678","volume":"20","author":"GT Barnes","year":"1994","unstructured":"Barnes GT, Duyao MP, Ambrose CM et al (1994) Mouse Huntingtons-disease gene homology (Hdh). Somat Cell Mol Genet 20(2):87\u201394","journal-title":"Somat Cell Mol Genet"},{"issue":"4","key":"10_CR49","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/ng1297-404","volume":"17","author":"JK White","year":"1997","unstructured":"White JK, Auerbach W, Duyao MP et al (1997) Huntingtin is required for neurogenesis and is not impaired by the Huntington\u2019s disease CAG expansion. Nat Genet 17(4):404\u2013410","journal-title":"Nat Genet"},{"issue":"4","key":"10_CR50","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/(SICI)1097-4547(19991115)58:4<515::AID-JNR5>3.0.CO;2-F","volume":"58","author":"MS Levine","year":"1999","unstructured":"Levine MS, Klapstein GJ, Koppel A et al (1999) Enhanced sensitivity to N-methyl-d-aspartate receptor activation in transgenic and knockin mouse models of Huntington\u2019s disease. J Neurosci Res 58(4):515\u2013532","journal-title":"J Neurosci Res"},{"issue":"2","key":"10_CR51","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/hmg\/10.2.137","volume":"10","author":"CH Lin","year":"2001","unstructured":"Lin CH, Tallaksen-Greene S, Chien WM et al (2001) Neurological abnormalities in a knock-in mouse model of Huntington\u2019s disease. Hum Mol Genet 10(2):137\u2013144","journal-title":"Hum Mol Genet"},{"issue":"5","key":"10_CR52","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/hmg\/8.5.763","volume":"8","author":"PF Shelbourne","year":"1999","unstructured":"Shelbourne PF, Killeen N, Hevner RF et al (1999) A Huntington\u2019s disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice. Hum Mol Genet 8(5):763\u2013774","journal-title":"Hum Mol Genet"},{"issue":"4","key":"10_CR53","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1093\/hmg\/9.4.503","volume":"9","author":"VC Wheeler","year":"2000","unstructured":"Wheeler VC, White JK, Gutekunst CA et al (2000) Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in Hdh(Q92) and Hdh(Q111) knock-in mice. Hum Mol Genet 9(4):503\u2013513","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10_CR54","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/cne.10776","volume":"465","author":"LB Menalled","year":"2003","unstructured":"Menalled LB, Sison JD, Dragatsis I et al (2003) Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington\u2019s disease with 140 CAG repeats. J Comp Neurol 465(1):11\u201326","journal-title":"J Comp Neurol"},{"issue":"19","key":"10_CR55","doi-asserted-by":"publisher","first-page":"3702","DOI":"10.1093\/hmg\/ddq285","volume":"19","author":"MY Heng","year":"2010","unstructured":"Heng MY, Duong DK, Albin RL et al (2010) Early autophagic response in a novel knock-in model of Huntington disease. Hum Mol Genet 19(19):3702\u20133720. https:\/\/doi.org\/10.1093\/hmg\/ddq285","journal-title":"Hum Mol Genet"},{"issue":"8","key":"10_CR56","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.4161\/auto.6.8.13617","volume":"6","author":"MY Heng","year":"2010","unstructured":"Heng MY, Detloff PJ, Paulson HL, Albin RL (2010) Early alterations of autophagy in Huntington disease-like mice. Autophagy 6(8):1206\u20131208","journal-title":"Autophagy"},{"key":"10_CR57","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1093\/brain\/awg077","volume":"126","author":"F Squitieri","year":"2003","unstructured":"Squitieri F, Gellera C, Cannella M et al (2003) Homozygosity for CAG mutation in Huntington disease is associated with more severe clinical course. Brain 126:946\u2013955","journal-title":"Brain"},{"issue":"7","key":"10_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0049838","volume":"12","author":"LB Menalled","year":"2012","unstructured":"Menalled LB, Kudwa AE, Miller S et al (2012) Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington\u2019s disease: zQ175. PLoS One 12(7):e49838. https:\/\/doi.org\/10.1371\/journal.pone.0049838 . [Epub 2012 Dec 20]","journal-title":"PLoS One"},{"key":"10_CR59","doi-asserted-by":"crossref","unstructured":"Southwell AL, Smith-Dijak A, Kay C et al (2016) An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes. Hum Mol Genet. Jul 4. pii: ddw212 [Epub ahead of print]","DOI":"10.1093\/hmg\/ddw212"},{"key":"10_CR60","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.pharmthera.2006.12.003","volume":"113","author":"C Gaveriaux-Ruff","year":"2007","unstructured":"Gaveriaux-Ruff C, Kieffer B (2007) Conditional gene targeting in the mouse nervous system: insights into brain function and diseases. Pharmacol Ther 113:619\u2013634","journal-title":"Pharmacol Ther"},{"key":"10_CR61","first-page":"533","volume-title":"Movement disorders: genetics and models","author":"G Mazarei","year":"2014","unstructured":"Mazarei G, Leavitt BR (2014) Murine models of HD. In: Movement disorders: genetics and models, 2nd edn. Elsevier, Amsterdam, pp 533\u2013546","edition":"2"},{"issue":"1","key":"10_CR62","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)80623-6","volume":"101","author":"A Yamamoto","year":"2000","unstructured":"Yamamoto A, Lucas JJ, Hen R (2000) Reversal of neuropathology and motor dysfunction in a conditional model of Huntington\u2019s disease. Cell 101(1):57\u201366","journal-title":"Cell"},{"issue":"20","key":"10_CR63","doi-asserted-by":"publisher","first-page":"9302","DOI":"10.1073\/pnas.91.20.9302","volume":"91","author":"PA Furth","year":"1994","unstructured":"Furth PA, St Onge L, Boger H et al (1994) Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. Proc Natl Acad Sci U S A 91(20):9302\u20139306","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"42","key":"10_CR64","doi-asserted-by":"publisher","first-page":"9773","DOI":"10.1523\/JNEUROSCI.3183-05.2005","volume":"25","author":"M D\u00edaz-Hern\u00e1ndez","year":"2005","unstructured":"D\u00edaz-Hern\u00e1ndez M, Torres-Peraza J, Salvatori-Abarca A et al (2005) Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington\u2019s disease. J Neurosci 25(42):9773\u20139781","journal-title":"J Neurosci"},{"issue":"52","key":"10_CR65","doi-asserted-by":"publisher","first-page":"22480","DOI":"10.1073\/pnas.0911503106","volume":"106","author":"J Bradford","year":"2009","unstructured":"Bradford J, Shin JY, Roberts M et al (2009) Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc Natl Acad Sci U S A 106(52):22480\u201322485. https:\/\/doi.org\/10.1073\/pnas.0911503106","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"10_CR66","doi-asserted-by":"publisher","first-page":"10653","DOI":"10.1074\/jbc.M109.083287","volume":"285","author":"J Bradford","year":"2010","unstructured":"Bradford J, Shin JY, Roberts M et al (2010) Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice. J Biol Chem 285(14):10653\u201310661","journal-title":"J Biol Chem"},{"issue":"15","key":"10_CR67","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1093\/hmg\/ddq212","volume":"19","author":"M Faideau","year":"2010","unstructured":"Faideau M, Kim J, Cormier K et al (2010) In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects. Hum Mol Genet 19(15):3053\u20133067","journal-title":"Hum Mol Genet"},{"issue":"20","key":"10_CR68","doi-asserted-by":"publisher","first-page":"5736","DOI":"10.1073\/pnas.1603871113","volume":"113","author":"AE Molero","year":"2016","unstructured":"Molero AE, Arteaga-Bracho EE, Chen CH et al (2016) Selective expression of mutant huntingtin during development recapitulates characteristic features of Huntington\u2019s disease. Proc Natl Acad Sci U S A 113(20):5736\u20135741","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10_CR69","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/hmg\/dds397","volume":"22","author":"AL Southwell","year":"2013","unstructured":"Southwell AL, Warby SC, Carroll JB et al (2013) A fully humanized transgenic mouse model of Huntington disease. Hum Mol Genet 22(1):18\u201334","journal-title":"Hum Mol Genet"},{"issue":"4","key":"10_CR70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094562","volume":"9","author":"K Kolodziejczyk","year":"2014","unstructured":"Kolodziejczyk K, Parsons MP, Southwell AL et al (2014) Striatal synaptic dysfunction and hippocampal plasticity deficits in the Hu97\/18 mouse model of Huntington disease. PLoS One 9(4):e94562. https:\/\/doi.org\/10.1371\/journal.pone.0094562 . eCollection 2014","journal-title":"PLoS One"},{"key":"10_CR71","unstructured":"Menalled L, Lutz C, Ramboz S et al (2014) A field guide to working with mouse models of Huntington\u2019s disease. http:\/\/chdifoundation.org\/a-field-guide-to-working-with-mouse-models-of-huntingtons-disease\/"},{"key":"10_CR72","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/dev.10079","volume":"42","author":"A Weller","year":"2003","unstructured":"Weller A, Leguisamo AC, Towns L et al (2003) Maternal effects in infant and adult phenotypes of 5HT1A and 5HT1B receptor knockout mice. Dev Psychobiol 42:194\u2013205","journal-title":"Dev Psychobiol"},{"issue":"3","key":"10_CR73","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1037\/0735-7044.113.3.587","volume":"113","author":"D Brunner","year":"1999","unstructured":"Brunner D, Buhot MC, Hen R, Hofer M (1999) Anxiety, motor activation and maternal infant interactions in 5HT1B knockout mice. Behav Neurosci 113(3):587\u2013601","journal-title":"Behav Neurosci"},{"issue":"2","key":"10_CR74","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/ana.10094","volume":"51","author":"E Hockly","year":"2002","unstructured":"Hockly E, Cordery PM, Woodman B et al (2002) Environmental enrichment slows disease progression in R6\/2 Huntington\u2019s disease mice. Ann Neurol 51(2):235\u2013242","journal-title":"Ann Neurol"},{"issue":"6","key":"10_CR75","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1037\/a0026033","volume":"125","author":"SJ Farley","year":"2011","unstructured":"Farley SJ, McKay BM, Disterhoft JF, Weiss C (2011) Reevaluating hippocampus dependent learning in FVB\/N mice. Behav Neurosci 125(6):871\u2013878","journal-title":"Behav Neurosci"},{"key":"10_CR76","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.brainres.2005.01.067","volume":"1040","author":"PE Schauwecker","year":"2005","unstructured":"Schauwecker PE (2005) Susceptibility to excitotoxic and metabolic striatal neurodegeneration in the mouse is genotype dependent. Brain Res 1040:112\u2013120","journal-title":"Brain Res"},{"key":"10_CR77","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.nbd.2006.12.010","volume":"26","author":"JM Raamsdonk Van","year":"2007","unstructured":"Van Raamsdonk JM, Metzler M, Slow E et al (2007) Phenotypic abnormalities in the YAC128 mouse model of Huntington\u2019s disease are penetrant on multiple genetic backgrounds and modulated by strain. Neurobiol Dis 26:189\u2013200","journal-title":"Neurobiol Dis"},{"key":"10_CR78","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.neulet.2011.11.063","volume":"507","author":"S Orvoen","year":"2012","unstructured":"Orvoen S, Pla P, Gardier AM, Saudou F, David DJ (2012) Huntington\u2019s disease knock-in male mice show specific anxiety-like behavior and altered neuronal maturation. Neurosci Lett 507:127\u2013132","journal-title":"Neurosci Lett"},{"issue":"19","key":"10_CR79","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1212\/01.wnl.0000334276.09729.0e","volume":"71","author":"NA Aziz","year":"2008","unstructured":"Aziz NA, van der Burg JM, Landwehrmeyer GB, Brunding P, Stijnen T, EHDI Study Group, Roos RA (2008) Weight loss in Huntington\u2019s disease increases with higher CAG repeat number. Neurology 71(19):1506\u20131513. https:\/\/doi.org\/10.1212\/01.wnl.0000334276.09729.0e","journal-title":"Neurology"},{"issue":"2","key":"10_CR80","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1089\/neu.1994.11.187","volume":"11","author":"RJ Hamm","year":"1994","unstructured":"Hamm RJ, Pike BR, O\u2019Dell DM, Lyeth BG, Jenkins LW (1994) The rotarod test: an evaluation of its effectiveness in assessing motor deficits following traumatic brain injury. J Neurotrauma 11(2):187\u2013196","journal-title":"J Neurotrauma"},{"key":"10_CR81","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.brainresbull.2008.10.007","volume":"78","author":"PN Pallier","year":"2009","unstructured":"Pallier PN, Drew CK, Morton AJ (2009) The detection and measurement of locomotor deficits in a transgenic mouse model of Huntington\u2019s disease are task-and-protocol dependent: influence of non-motor factors on locomotor function. Brain Res Bull 78:347\u2013355","journal-title":"Brain Res Bull"},{"key":"10_CR82","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S0361-9230(03)00185-0","volume":"61","author":"E Hockly","year":"2003","unstructured":"Hockly E (2003) Standardization and statistical approaches to therapeutic trials in the R6\/2 mouse. Brain Res Bull 61:469\u2013479","journal-title":"Brain Res Bull"},{"issue":"1","key":"10_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2005.01.024","volume":"20","author":"MA Hickey","year":"2005","unstructured":"Hickey MA, Gallant K, Gross GG, Levine MS, Chesselet MF (2005) Early behavioral deficits in R6\/2 mice suitable for use in preclinical drug testing. Neurobiol Dis 20(1):1\u201311","journal-title":"Neurobiol Dis"},{"key":"10_CR84","first-page":"62","volume-title":"Huntington's disease","author":"D Craufurd","year":"2002","unstructured":"Craufurd D, Snowden J (2002) Neuropsychological and neuropsychiatric aspects of Huntington\u2019s disease. In: Bates G, Harper PS, Jones L (eds) Huntington's disease, 3rd edn. Oxford University Press, Oxford, pp 62\u201394","edition":"3"},{"issue":"1","key":"10_CR85","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/0165-0270(84)90007-4","volume":"11","author":"R Morris","year":"1984","unstructured":"Morris R (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11(1):47\u201360","journal-title":"J Neurosci Methods"},{"issue":"2","key":"10_CR86","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/0304-3940(93)90752-7","volume":"149","author":"F Block","year":"1993","unstructured":"Block F, Kunkel M, Schwarz M (1993) Quinolinic acid lesion of the striatum induces impairment in spatial learning and motor performance in rats. Neurosci Lett 149(2):126\u2013128","journal-title":"Neurosci Lett"},{"key":"10_CR87","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.bbr.2012.10.039","volume":"238","author":"YS Abada","year":"2013","unstructured":"Abada YS, Schreiber R, Ellebroek B (2013) Motor, emotional and cognitive deficits in adult BACHD mice: a model for Huntington\u2019s disease. Behav Brain Res 238:243\u2013251","journal-title":"Behav Brain Res"},{"key":"10_CR88","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S0006-8993(98)00736-7","volume":"805","author":"SE File","year":"1998","unstructured":"File SE, Mahal A, Mangiarini L, Bates GP (1998) Striking changes in anxiety in Huntington\u2019s disease transgenic mice. Brain Res 805:234\u2013240","journal-title":"Brain Res"},{"key":"10_CR89","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.chembiol.2011.12.020","volume":"19","author":"B Baldo","year":"2012","unstructured":"Baldo B, Paganetti P, Grueninger S et al (2012) TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant huntingtin in Huntington\u2019s disease. Chem Biol 19:264\u2013275","journal-title":"Chem Biol"},{"key":"10_CR90","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1093\/hmg\/ddp467","volume":"19","author":"K Sathasivam","year":"2010","unstructured":"Sathasivam K, Lane A, Legleiter J et\u00a0al (2010) Identical oligomeric and fibrillar structures captured from the brains of R6\/2 and knock-in mouse models of Huntington\u2019s disease. Hum Mol Genet 19:65\u201378","journal-title":"Hum Mol Genet"},{"key":"10_CR91","doi-asserted-by":"publisher","first-page":"4392","DOI":"10.1529\/biophysj.107.112102","volume":"93","author":"WF Weiss","year":"2007","unstructured":"Weiss WF, Hodgdon TK, Kaler EW, Lenhoff AM, Roberts CJ et al (2007) Nonnative protein polymers: structure, morphology, and relation to nucleation and growth. Biophys J 93:4392\u20134403","journal-title":"Biophys J"},{"issue":"15","key":"10_CR92","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0155834","volume":"11","author":"Z Bayram-Weston","year":"2016","unstructured":"Bayram-Weston Z, Jones L, Dunnet SB, Brooks SP (2016) Comparison of mHTT antibodies in Huntington\u2019s disease mouse models reveal specific binding profiles and steady state ubiquitin levels with disease development. PLoS One 11(15):e0155834. https:\/\/doi.org\/10.1371\/journal.pone.0155834","journal-title":"PLoS One"},{"issue":"7","key":"10_CR93","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160295","volume":"11","author":"A Labadorf","year":"2015","unstructured":"Labadorf A, Hoss AG, Lagomarsino V et al (2015) RNA sequence analysis of human Huntington disease brain reveals an extensive increase in inflammatory and developmental gene expression. PLoS One 11(7):e0160295. https:\/\/doi.org\/10.1371\/journal.pone.0160295","journal-title":"PLoS One"},{"issue":"14","key":"10_CR94","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/hmg\/ddw142","volume":"25","author":"JRC Miller","year":"2016","unstructured":"Miller JRC, Lo KK, Andre R et al (2016) RNA-Seq of Huntington\u2019s disease patient myeloid cells reveals innate transcriptional dysregulation associated with proinflammatory pathway activation. Hum Mol Genet 25(14):2893\u20132904. https:\/\/doi.org\/10.1093\/hmg\/ddw142","journal-title":"Hum Mol Genet"},{"key":"10_CR95","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.nbd.2011.03.018","volume":"43","author":"JB Carroll","year":"2011","unstructured":"Carroll JB, Lerch JP, Franicosi S et al (2011) Natural history of disease in the YAC128 mouse reveals a discrete signature of pathology in Huntington disease. Neurobiol Dis 43:257\u2013265","journal-title":"Neurobiol Dis"},{"key":"10_CR96","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050717","volume":"7","author":"T Heikkinen","year":"2012","unstructured":"Heikkinen T, Lehtimaki K, Vartiainen N et al (2012) Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington\u2019s disease. PLoS One 7:e50717","journal-title":"PLoS One"},{"key":"10_CR97","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.neuroscience.2008.08.041","volume":"157","author":"MA Hickey","year":"2008","unstructured":"Hickey MA, Kosmalska A, Enayati J et\u00a0al (2008) Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington\u2019s disease mice. Neuroscience 157:280\u2013295","journal-title":"Neuroscience"},{"key":"10_CR98","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.beproc.2011.10.011","volume":"89","author":"D Brunner","year":"2012","unstructured":"Brunner D, Balci F, Ludvig EA (2012) Comparative psychology and the grand challenge of drug discovery in psychiatry and neurodegeneration. Behav Process 89:187\u2013195","journal-title":"Behav Process"},{"issue":"29","key":"10_CR99","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1002\/mds.26006","volume":"15","author":"LM Menalled","year":"2014","unstructured":"Menalled LM, Brunner D (2014) Animal models of Huntington\u2019s disease for translation to the clinic: best practices. Mov Disord 15(29):1375\u20131390. https:\/\/doi.org\/10.1002\/mds.26006","journal-title":"Mov Disord"},{"issue":"11","key":"10_CR100","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1002\/mds.26007","volume":"29","author":"E Wild","year":"2014","unstructured":"Wild E, Tabrizi SJ (2014) Targets for future clinical trials in Huntington\u2019s disease: what\u2019s in the pipeline? Mov Disord 29(11):1434\u20131445. https:\/\/doi.org\/10.1002\/mds.26007","journal-title":"Mov Disord"},{"issue":"1","key":"10_CR101","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13024-016-0128-x","volume":"11","author":"C Pavon-Agustin","year":"2016","unstructured":"Pavon-Agustin C, Mielcarek M, Canut-Garriga M, Isalan M (2016) Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice. Mol Neurodegener 11(1):64. https:\/\/doi.org\/10.1186\/s13024-016-0128-x","journal-title":"Mol Neurodegener"},{"issue":"45","key":"10_CR102","doi-asserted-by":"publisher","first-page":"E3136","DOI":"10.1073\/pnas.1206506109","volume":"109","author":"M Garriga-Canut","year":"2012","unstructured":"Garriga-Canut M, Agustin-Pavon C, Herrmann F et al (2012) Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6\/2 mice. Proc Natl Acad Sci U S A 109(45):E3136\u2013E3145. https:\/\/doi.org\/10.1073\/pnas.1206506109","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10_CR103","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0171127","volume":"12","author":"NA Dalston","year":"2017","unstructured":"Dalston NA, Gonzalez-Barriga A, Kourkouta E et al (2017) The expanded CAG repeat in the huntingtin gene as a target for therapeutic RNA modulation throughout the HD mouse brain. PLoS One 12(2):e0171127. https:\/\/doi.org\/10.1371\/journal.pone.0171127","journal-title":"PLoS One"},{"issue":"11","key":"10_CR104","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1172\/JCI83185","volume":"126","author":"L Rue","year":"2016","unstructured":"Rue L, Coronel-Banez M, Muncunil-Creus J et\u00a0al (2016) Targeting CAG repeat RNAs reduces Huntington\u2019s disease phenotype independently of huntingtin levels. J Clin Invest 126(11):4319\u20134330. https:\/\/doi.org\/10.1172\/JCI83185","journal-title":"J Clin Invest"},{"issue":"1","key":"10_CR105","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j-ymthe.2016.11.010","volume":"25","author":"AM Monteys","year":"2017","unstructured":"Monteys AM, Ebanks SA, Kesier MS, Davidson BL (2017) CRISPR\/Cas9 editing of the mutant huntingtin allele in vitro and in vivo. Mol Ther 25(1):12\u201323. https:\/\/doi.org\/10.1016\/j-ymthe.2016.11.010","journal-title":"Mol Ther"},{"issue":"9","key":"10_CR106","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1172\/JCI80339","volume":"126","author":"IH Kratter","year":"2016","unstructured":"Kratter IH, Zahed H, Lau A et al (2016) Serine 421 regulates huntingtin toxicity and clearance in mice. J Clin Invest 126(9):3585\u20133597. https:\/\/doi.org\/10.1172\/JCI80339","journal-title":"J Clin Invest"},{"issue":"3","key":"10_CR107","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.neuron.2016.03.016","volume":"90","author":"J Ochaba","year":"2016","unstructured":"Ochaba J, Monteys AM, O\u2019Rourke JG et al (2016) PIAS1 regulates mutant huntingtin accumulation and Huntington\u2019s disease-associated phenotypes in vivo. Neuron 90(3):507\u2013520. https:\/\/doi.org\/10.1016\/j.neuron.2016.03.016","journal-title":"Neuron"},{"issue":"2","key":"10_CR108","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.neuron.2014.12.019","volume":"85","author":"JH Lee","year":"2015","unstructured":"Lee JH, Tecedor L, Chen YH et al (2015) Reinstating aberrant mTORC1 activity in Huntington\u2019s disease mice improves disease phenotype. Neuron 85(2):303\u2013315. https:\/\/doi.org\/10.1016\/j.neuron.2014.12.019","journal-title":"Neuron"},{"issue":"4","key":"10_CR109","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3233\/JHD-160226","volume":"5","author":"V Chopra","year":"2016","unstructured":"Chopra V, Quinti L, Khanna P et al (2016) LBH589, a hydroxamic acid-derived HDAC inhibitor is neuroprotective in mouse models of Huntington\u2019s disease. J Huntingtons Dis 5(4):347\u2013355","journal-title":"J Huntingtons Dis"},{"issue":"11","key":"10_CR110","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1111\/jcmm.12604","volume":"19","author":"F Squitieri","year":"2015","unstructured":"Squitieri F, Di Pardo A, Favellato M, Amico E, Maglione V, Frati L (2015) Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6\/2 mouse model. J Cell Mol Med 19(11):2540\u20132548. https:\/\/doi.org\/10.1111\/jcmm.12604","journal-title":"J Cell Mol Med"},{"issue":"18","key":"10_CR111","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1093\/hmg\/ddw238","volume":"25","author":"M Geva","year":"2016","unstructured":"Geva M, Kusko R, Soares H et al (2016) Pridopidine activates neuroprotective pathways impaired in Huntington\u2019s disease. Hum Mol Genet 25(18):3975\u20133987. https:\/\/doi.org\/10.1093\/hmg\/ddw238","journal-title":"Hum Mol Genet"},{"issue":"Pt A","key":"10_CR112","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.nbd.2016.10.006","volume":"97","author":"D Ryskamp","year":"2017","unstructured":"Ryskamp D, Wu J, Geva M, Kusko R, Grossman I, Hayden M, Bezprozvanny I (2017) The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington\u2019s disease. Neurobiol Dis 97(Pt A):46\u201359. https:\/\/doi.org\/10.1016\/j.nbd.2016.10.006","journal-title":"Neurobiol Dis"},{"issue":"3","key":"10_CR113","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3233\/JHD-140110","volume":"3","author":"J Corey-Bloom","year":"2014","unstructured":"Corey-Bloom J, Jia H, Aikin AM, Thomas EA (2014) Disease modifying potential of glatiramer acetate in Huntington\u2019s disease. J Huntingtons Dis 3(3):311\u2013316. https:\/\/doi.org\/10.3233\/JHD-140110","journal-title":"J Huntingtons Dis"},{"key":"10_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/srep33861","volume":"6","author":"T Imamura","year":"2016","unstructured":"Imamura T, Fujita K, Tagawa K et al (2016) Identification of hepta-histidine as a candidate drug for Huntington\u2019s disease by in silico-in vitro-in vivo-integrated screens of chemical libraries. Sci Rep 6:33861. https:\/\/doi.org\/10.1038\/srep33861","journal-title":"Sci Rep"},{"key":"10_CR115","doi-asserted-by":"publisher","DOI":"10.1038\/srep31652","volume":"6","author":"M Garcia-Miralles","year":"2016","unstructured":"Garcia-Miralles M, Hong X, Tan JL et al (2016) Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioral improvements in the YAC128 model of Huntington\u2019s disease. Sci Rep 6:31652. https:\/\/doi.org\/10.1038\/srep31652","journal-title":"Sci Rep"},{"issue":"1","key":"10_CR116","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s133-014-0304-z","volume":"12","author":"S Valdeolivas","year":"2015","unstructured":"Valdeolivas S, Navarrete C, Cantarero I, Bellido ML, Munoz E, Sagredo O (2015) Neuroprotective properties of cannabigerol in Huntington\u2019s disease: studies in R6\/2 mice and 3-nitropropionate-lesioned mice. Neurotherapeutics 12(1):185\u2013199. https:\/\/doi.org\/10.1007\/s133-014-0304-z","journal-title":"Neurotherapeutics"},{"key":"10_CR117","doi-asserted-by":"publisher","DOI":"10.1038\/srep29789","volume":"6","author":"J Diaz-Alonso","year":"2016","unstructured":"Diaz-Alonso J, Paraiso-Luna J, Navarrete C et al (2016) VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington\u2019s disease. Sci Rep 6:29789. https:\/\/doi.org\/10.1038\/srep29789","journal-title":"Sci Rep"},{"key":"10_CR118","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2014.131","volume":"5","author":"DJ Wright","year":"2015","unstructured":"Wright DJ, Renoir T, Smith ZM et al (2015) N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6\/1 mouse model of Huntington\u2019s disease. Transl Psychiatry 5:e492. https:\/\/doi.org\/10.1038\/tp.2014.131","journal-title":"Transl Psychiatry"}],"container-title":["Methods in Molecular Biology","Huntington\u2019s Disease"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-7825-0_10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T18:26:29Z","timestamp":1571423189000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-7825-0_10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9781493978243","9781493978250"],"references-count":118,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-7825-0_10","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1007\/978-1-4939-7825-0","asserted-by":"object"}]},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}